Table 3 Iron replacement treatment episodes preceded and/or followed by a biological assessment [transferrin saturation index and/or serum ferritin]—from French healthcare coverage databases (EGB) 2006–2013, detail of patients with chronic inflammatory diseases.
Assessment before treatment | Assessment after treatment | Assessment before AND after treatment | ||||
|---|---|---|---|---|---|---|
n | (%) | n | (%) | n | (%) | |
Iron replacement therapy—patients with chronic heart failure (n = 5,244 episodes) | ||||||
Transferrin saturation (TSAT) | 116 | (2.2) | 70 | (1.3) | ||
Ferritin | 1524 | (29.1) | 1,237 | (23.6) | ||
TSAT or ferritin | 1728 | (33.0) | 1,296 | (24.7) | 589 | (11.2) |
Iron replacement therapy—patients with inflammatory bowel disease (n = 2,548 episodes) | ||||||
TSAT | 51 | (3.3) | 40 | (2.6) | ||
Ferritin | 670 | (43.5) | 614 | (39.8) | ||
TSAT or ferritin | 766 | (49.7) | 632 | (41.0) | 453 | (29.4) |
Iron replacement therapy—patients with chronic kidney disease (n = 1,034 episodes) | ||||||
TSAT | 29 | (2.8) | 16 | (1.5) | ||
Ferritin | 443 | (42.8) | 283 | (27.4) | ||
TSAT or ferritin | 501 | (48.5) | 295 | (28.5) | 199 | (19.2) |
Iron replacement therapy—patients with cancer (n = 10 591 episodes) | ||||||
TSAT | 190 | (1.8) | 121 | (1.1) | ||
Ferritin | 3,103 | (29.3) | 2,300 | (21.7) | ||
TSAT or ferritin | 3,504 | (33.1) | 2,396 | (22.6) | 1,124 | (10.6) |
Iron replacement therapy—patients with another chronic disease (n = 16 014 episodes) | ||||||
TSAT | 274 | (1.7) | 184 | (1.1) | ||
Ferritin | 5,199 | (32.5) | 3,570 | (22.3) | ||
TSAT or ferritin | 5,417 | (33.8) | 3,702 | (23.1) | 1779 | (11.1) |
